
Patient Selection and Sequencing of CELMoDs in Relapsed/Refractory Multiple Myeloma
The faculty discuss how iberdomide, in combination with daratumumab and dexamethasone, may fit into treatment selection and sequencing for relapsed/refractory multiple myeloma.
The faculty discuss how iberdomide, in combination with daratumumab and dexamethasone, may fit into treatment selection and sequencing for relapsed/refractory multiple myeloma. Dr. Joshua Richter and the panel consider how prior anti-CD38 exposure, relapse characteristics, disease risk, and treatment readiness may influence patient selection. They highlight the potential role of this regimen as an accessible, non-T-cell-redirecting option for selected patients at early relapse, including those who may not be ready for CAR T-cell therapy. The discussion also addresses the significance of MRD-negative complete response as the primary endpoint supporting regulatory approval, while recognizing the need for continued follow-up to establish whether these responses translate into longer progression-free survival and ultimately overall survival. Faculty consider how CELMoD-based treatment may preserve future therapeutic options and support individualized sequencing as the relapsed/refractory multiple myeloma treatment landscape evolves. They also discuss the potential relevance of an oral regimen in community practice, where access to specialized T-cell-redirecting therapies may be more limited.
Related to this article








